GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways
Authors:
- Laura GuerenneLGLaura Guerenne
- Stéphanie BeurletSBStéphanie Beurlet
- Mohamed SaidMSMohamed Said
- Petra GorombeiPGPetra Gorombei
- Carole Le PogamCPCarole Le Pogam
- Fabien GuidezFGFabien Guidez
- Pierre de la GrangePGPierre de la Grange
- Nader OmidvarNONader Omidvar
- Valérie VanneauxVVValérie Vanneaux
- Ken MillsKen Mills
- Ghulam J MuftiGMGhulam J Mufti
- Laure Sarda-MantelLSLaure Sarda-Mantel
Open Access
- 27 January 2016
- journal article
- research article
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 9 (1) , 1-20
Abstract
In spite of the recent discovery of genetic mutations in most myelodysplasic (MDS) patients, the pathophysiology of these disorders still remains poorly understood, and only few in vivo models are available to help unravel the disease. We performed global specific gene expression profiling and functional pathway analysis in purified Sca1+ cells of two MDS transgenic mouse models that mimic human high-risk MDS (HR-MDS) and acute myeloid leukemia (AML) post MDS, with NRASD12 and BCL2 transgenes under the control of different promoters MRP8NRASD12/tethBCL-2 or MRP8[NRASD12/hBCL-2], respectively. Analysis of dysregulated genes that were unique to the diseased HR-MDS and AML post MDS mice and not their founder mice pointed first to pathways that had previously been reported in MDS patients, including DNA replication/damage/repair, cell cycle, apoptosis, immune responses, and canonical Wnt pathways, further validating these models at the gene expression level. Interestingly, pathways not previously reported in MDS were discovered. These included dysregulated genes of noncanonical Wnt pathways and energy and lipid metabolisms. These dysregulated genes were not only confirmed in a different independent set of BM and spleen Sca1+ cells from the MDS mice but also in MDS CD34+ BM patient samples. These two MDS models may thus provide useful preclinical models to target pathways previously identified in MDS patients and to unravel novel pathways highlighted by this study.Keywords
This publication has 92 references indexed in Scilit:
- Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromesLeukemia, 2012
- Altered Hematopoietic Cell Gene Expression Precedes Development of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia and Identifies Patients at RiskCancer Cell, 2011
- Bone progenitor dysfunction induces myelodysplasia and secondary leukaemiaNature, 2010
- Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cellsLeukemia, 2010
- Principles of Cancer Therapy: Oncogene and Non-oncogene AddictionCell, 2009
- Systematic and integrative analysis of large gene lists using DAVID bioinformatics resourcesNature Protocols, 2008
- Sumoylation and the function of CCAAT enhancer binding protein alpha (C/EBPα)Blood Cells, Molecules, and Diseases, 2008
- C. elegans AP-2 and Retromer Control Wnt Signaling by Regulating MIG-14/WntlessDevelopmental Cell, 2008
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences, 2005
- PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetesNature Genetics, 2003